ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Antibody-drug Conjugate BL-M17D1

In Sichuan Biokin Pharmaceutical’s pipeline, HER2 ADC. Its studies are mostly in Breast Neoplasms · Esophageal Neoplasms, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since Jul 8, 20243 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical32 open or runningphase 1since Jul 8, 2024Jul 8, 2024none ahead
  • Named in Sichuan Biokin Pharmaceutical’s own pipeline as BL-M17D1 (HER2 ADC), phase 1, as of Nov 16, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2024First studies: 2 phase 1 studiesFirst studyNCT06500052, NCT06503783
  2. Nov 27, 2024Phase 1 study in Breast NeoplasmsNCT06714617 · 3 enrolled · United States

TargetBeta

“HER2 ADC”the company's pipeline, read by Claude · source

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06714617Breast Neoplasms · United States1TerminatedJan 30, 20263
NCT06503783Breast Neoplasms · China1RecruitingAug 202620
NCT06500052Esophageal Neoplasms · China1RecruitingAug 202620

How it is read

Names in the registry

  • “BL-M17D1”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.